Cantargia AB (publ) (CANTA.ST)
Develops antibody drugs targeting IL1RAP to treat cancer and autoimmune diseases
1.90+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-41.4%
The outlook
CANTA.ST trades well below both its 50- and 200-day moving averages, sitting near its 52-week low. Analyst sentiment is mixed, with an average price target suggesting significant upside from current levels, though coverage appears limited. The overall score leans bearish, reflecting the stock's weak near-term technical position.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +428% vs current price
Analyst price target
~12-month · 2 analysts10.00average target+427.7% vs now
Now 1.90
Low 6.00High 14.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$471.1M
52-wk high
6.59
52-wk low
1.80
50-day avg
2.22
200-day avg
3.66
Trailing P/E
3.0